Source from: Dr. John Campbell’s Youtube Channel
Fenbendazole and Cancer: Case Study Review
Overview
Fenbendazole (FBZ) is an inexpensive, widely available antiparasitic drug traditionally used in veterinary medicine. Its patent expired in the early 1990s, making it available as a generic medication. In recent years, FBZ has drawn attention for its potential anticancer properties, supported by case studies suggesting tumor regression and remission in advanced cancers.
Case 1: Stage IV Breast Cancer (83-Year-Old Female)
Background
- Diagnosed with breast cancer in 2009 → treated with bilateral mastectomy.
- Cancer recurred in October 2021 with liver, spine, and bone metastases confirmed through MRI and PET/CT.
- PET/CT (Dec 29, 2021) revealed multiple hypermetabolic lesions in lungs, liver, and bones (largest 5.0 × 2.9 cm in L4 vertebra).
Treatment Path
- Declined further chemotherapy or radiation; entered hospice care.
- Nov 22, 2021: Began self-administering FBZ (222 mg/day).
- Dec 2021: Received fulvestrant injection (estrogen receptor blocker).
- Jan 2022: Underwent targeted radiation to two spinal metastases → tumors disappeared within days, pain resolved.
Response and Outcome
- Continued FBZ 222 mg/day for 8 months.
- Liver enzymes normalized, and CA 27.29 tumor marker dropped from 316 → 36.6 (Nov 2021 → Jul 2022).
- Apr 20, 2022 PET scan: No abnormal metabolic activity (complete remission).
- Jun 2022: Confirmed no active disease; all treatments discontinued.
- Continued FBZ daily and vitamin D (5,000 IU) + multivitamin.
- No adverse effects reported.
- Remains recurrence-free nearly 3 years post-remission.
Case 2: Metastatic Prostate Cancer (75-Year-Old Male)
Background
- Metastases in spine, pelvic bones, and right humeral head confirmed by bone and CT scans.
- Received conventional and complementary therapies.
Treatment Path and Response
- Added FBZ to ongoing regimen.
- Notable regression of metastatic lesions and undetectable PSA levels sustained.
- After 26 months, patient remains in near-complete response and continues FBZ with standard therapy.
- No adverse effects observed.
Case 3: Melanoma (63-Year-Old Male)
Background
- Presented with hip mass; biopsy confirmed melanoma.
- PET-CT showed multiple hypermetabolic nodules in peritoneum, retroperitoneum, stomach, small bowel, and bones (L5 vertebra, gluteal muscles).
Treatment Path and Response
- Received conventional and complementary treatments along with FBZ.
- Achieved complete remission, remaining recurrence-free for 11 months post-remission.
- No reported side effects during treatment.
General Observations
- Across all three cases, FBZ was well tolerated with no adverse effects at the reported doses.
- Tumor regression and complete or near-complete remission occurred in multiple advanced-stage cancers.
- Supplementation (vitamin D and multivitamins) was commonly maintained.
- Joe Tippens Protocol is often cited as the self-administered framework for FBZ use.
Conclusion
Fenbendazole demonstrates significant potential as a repurposed anticancer therapy. The consistent remission and regression observed in these case studies highlight the need for formal clinical trials to evaluate its efficacy, dosing, and mechanisms of action in oncology.
Fenbendazole Case Report –
Joe Tipp’s Protocol
https://www.fenbendazole.org/fenbendazole-information/fenbendazole-dosage-guide